Logo
x

Search

Subscribe Now

Primary

Vifor and Angion's ANG-3777 Fail to Meet its Primary and Secondary Endpoint for Patients with High-Risk Kidney Transplant

Vifor and Angion's ANG-3777 Fail to Meet its Primary and Secondary Endpoint for Patients with High-Risk Kidney Transplant

  • October 27, 2021
Genentech's Ocrevus Shorter 2-Hour Infusion Receives the US FDA's Approval for Relapsing & Primary Progressive Multiple Sclerosis

Genentech's Ocrevus Shorter 2-Hour Infusion Receives the US FDA's Approval for Relapsing & Primary Progressive Multiple Sclerosis

  • December 15, 2020
Alnylam's Oxlumo (lumasiran) Receives the US FDA's Approval for Treatment of Primary Hyperoxaluria Type 1 in Pediatric and Adult Patients

Alnylam's Oxlumo (lumasiran) Receives the US FDA's Approval for Treatment of Primary Hyperoxaluria Type 1 in Pediatric and Adult P...

  • November 25, 2020
Sobi's Gamifant (emapalumab) Receives FDA Approval for Primary Haemophagocytic Lymphohistiocytosis (HLH)

Sobi's Gamifant (emapalumab) Receives FDA Approval for Primary Haemophagocytic Lymphohistiocytosis (HLH)

  • November 10, 2018
AstraZeneca’s Fasenra Receives NMPA’s Approval to Treat Severe Eosinophilic Asthma

    AstraZeneca’s Fasenra Receives NMPA’s Approval to Treat Severe Eosinophilic Asthma

    • August 21, 2024
    US FDA Grants Accelerated Approval to Gilead’s Livdelzi (Seladelpar) to Treat Primary Biliary Cholangitis (PBC)

      US FDA Grants Accelerated Approval to Gilead’s Livdelzi (Seladelpar) to Treat Primary Biliary Cholangitis (PBC)

      • August 16, 2024
      META Pharmaceuticals’ META-001-PH Receives the US FDA’s Rare Pediatric Disease Designation to Treat Primary Hyperoxaluria

        META Pharmaceuticals’ META-001-PH Receives the US FDA’s Rare Pediatric Disease Designation to Treat Primary Hyperoxaluria

        • August 6, 2024
        Calliditas Reports Results from P-IIb (TRANSFORM) Study of Setanaxib for Treating Primary Biliary Cholangitis

          Calliditas Reports Results from P-IIb (TRANSFORM) Study of Setanaxib for Treating Primary Biliary Cholangitis

          • July 26, 2024
          Insights+: The US FDA New Drug Approvals in June 2024

            Insights+: The US FDA New Drug Approvals in June 2024

            • July 16, 2024
            Botanix Pharmaceuticals’ Sofdra (Sofpironium) Receives the US FDA’s Approval to Treat Primary Axillary Hyperhidrosis

              Botanix Pharmaceuticals’ Sofdra (Sofpironium) Receives the US FDA’s Approval to Treat Primary Axillary Hyperhidrosis

              • June 20, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.